Senti Bio Raises $105m Series B Round For CAR-NKs, Led By Leaps For Bayer
Company Anticipates IND Filing In 2022-2023
Executive Summary
The investment is the latest in Bayer’s series of moves into cell and gene therapy, amid growing industry interest in CAR-NKs.
You may also be interested in...
Finance Watch: Amylyx, CinCor And Vigil Ready The First Biopharma IPOs Of 2022
Public Company Edition: Mergers with special purpose acquisition corporations also continue to take companies public, with three new SPAC offerings in late 2021. Also, Xeris raised $30m in a private placement of stock to support its recently approved drug and Sirnaomics went public in Hong Kong.
Bayer Back In Radiopharmaceuticals Ring With Noria Buy
Although Bayer's radiopharmaceutical for prostate cancer Xofigo has proved a commercial disappointment, the Leverkusen-headquartered firm is keen to advance its pipeline of targeted alpha therapies, snapping up Noria and its subsidiary PSMA Therapeutics.
GC LabCell Taps Alliances In Bid For Lead NK Cell Position
After accumulating technologies to develop off-the-shelf, allogeneic NK cell therapies over the past decade, Korea's GC LabCell is now tapping into the global market as US partner Artiva begins clinical trials of its lead asset.